GGrantIndex
← Leaderboards

Gaya K. Amarasinghe

Washington University

$21,435,025
Attributed
$28,678,949
Total exposure
15
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.6M · FY200925
$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$52,132,853 · 16

By mechanism

P01$32,126,877 · 5
R01$16,891,655 · 6
R41$1,160,409 · 2
R42$977,449 · 1
R56$533,763 · 1
R21$442,700 · 1

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Viral

Research focus

ViralProteinsDisease OutbreaksVirusBiochemicalVirus ReplicationInnovationCellsVirus DiseasesIntegration Host FactorsPathogenMolecularEbola VirusComplexInfectionInsightGlobal HealthIn VitroResearch PersonnelProteomicsRna VirusesViral RnaBindingBase

Grant awards (61)

Molecular Mechanisms of Filoviral-host Interactions$3,374,001
P01 · FY2025 · AI · contact PI
Biochemical and structural mechanisms at the filoviral-host interface$1,099,141
P01 · FY2025 · AI · contact PI
Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral$977,449
R42 · FY2025 · AI
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses$767,375
R01 · FY2025 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$731,052
R01 · FY2025 · AI · contact PI
Administrative Core$209,668
P01 · FY2025 · AI · contact PI
Molecular Mechanisms of Filoviral-host Interactions$3,374,001
P01 · FY2024 · AI · contact PI
Biochemical and structural mechanisms at the filoviral-host interface$1,189,295
P01 · FY2024 · AI · contact PI
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses$767,375
R01 · FY2024 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$735,323
R01 · FY2024 · AI · contact PI
Administrative Core$270,082
P01 · FY2024 · AI · contact PI
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.$194,975
R21 · FY2024 · AI · contact PI
Molecular Mechanisms of Filoviral-host Interactions$3,354,992
P01 · FY2023 · AI · contact PI
Biochemical and structural mechanisms at the filoviral-host interface$1,112,463
P01 · FY2023 · AI · contact PI
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses$783,556
R01 · FY2023 · AI · contact PI
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection$762,140
R01 · FY2023 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$739,505
R01 · FY2023 · AI · contact PI
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2$638,713
R01 · FY2023 · AI · contact PI
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2$388,750
R01 · FY2023 · AI · contact PI
Administrative Core$275,156
P01 · FY2023 · AI · contact PI
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy$272,089
R41 · FY2023 · AI
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.$247,725
R21 · FY2023 · AI · contact PI
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection$61,201
R01 · FY2023 · AI · contact PI
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection$774,291
R01 · FY2022 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$742,007
R01 · FY2022 · AI · contact PI
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2$649,870
R01 · FY2022 · AI · contact PI
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2$393,750
R01 · FY2022 · AI · contact PI
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy$296,536
R41 · FY2022 · AI
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection$786,333
R01 · FY2021 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$756,494
R01 · FY2021 · AI · contact PI
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2$667,277
R01 · FY2021 · AI · contact PI
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses$291,845
R41 · FY2021 · AI
Structural and Functional Characterization of the Ebola Virus Replication Complex$2,554,916
P01 · FY2020 · AI · contact PI
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection$796,422
R01 · FY2020 · AI · contact PI
Structural Mechanisms of Ebola Virus RNA Synthesis$773,062
P01 · FY2020 · AI · contact PI
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses$299,939
R41 · FY2020 · AI
Structural and Functional Studies of Ebola Virus RNA Synthesis$140,854
P01 · FY2020 · AI · contact PI
Structural and Functional Characterization of the Ebola Virus Replication Complex$2,563,154
P01 · FY2019 · AI · contact PI
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection$832,743
R01 · FY2019 · AI · contact PI
Structural Mechanisms of Ebola Virus RNA Synthesis$703,476
P01 · FY2019 · AI · contact PI
Structural and Functional Studies of Ebola Virus RNA Synthesis$140,126
P01 · FY2019 · AI · contact PI
Structural and Functional Characterization of the Ebola Virus Replication Complex$2,613,671
P01 · FY2018 · AI · contact PI
Multi-platform High Throughput Screens for Filoviral Replication Inhibitors$704,845
R01 · FY2018 · AI · contact PI
Structural Mechanisms of Ebola Virus RNA Synthesis$654,142
P01 · FY2018 · AI · contact PI
Structural and Functional Studies of Ebola Virus RNA Synthesis$169,017
P01 · FY2018 · AI · contact PI
Structural and Functional Characterization of the Ebola Virus Replication Complex$2,742,882
P01 · FY2017 · AI · contact PI
Multi-platform High Throughput Screens for Filoviral Replication Inhibitors$808,703
R01 · FY2017 · AI · contact PI
Structural Mechanisms of Ebola Virus RNA Synthesis$750,810
P01 · FY2017 · AI · contact PI
DEVELOPMENT, VALIDATION, AND OPTIMIZATION OF HTS SCREENS TARGETING NIPAH AND HENDRA VIRUS RNA SYNTHESIS$533,763
R56 · FY2017 · AI · contact PI
Structural and Functional Studies of Ebola Virus RNA Synthesis$209,451
P01 · FY2017 · AI · contact PI
Structural and Functional Characterization of the Ebola Virus Replication Complex$2,876,287
P01 · FY2016 · AI · contact PI
Structural Mechanisms of Ebola Virus RNA Synthesis$793,286
P01 · FY2016 · AI · contact PI
Multi-platform High Throughput Screens for Filoviral Replication Inhibitors$611,960
R01 · FY2016 · AI · contact PI
Structural and Functional Studies of Ebola Virus RNA Synthesis$182,944
P01 · FY2016 · AI · contact PI
Multi-platform High Throughput Screens for Filoviral Replication Inhibitors$23,064
R01 · FY2016 · AI · contact PI
Structural studies of Ebola VP35 mediated immune evasion mechanisms$350,092
R01 · FY2013 · AI · contact PI
Structural studies of Ebola VP35 mediated immune evasion mechanisms$372,438
R01 · FY2012 · AI · contact PI
Structural studies of Ebola VP35 mediated immune evasion mechanisms$243,200
R01 · FY2011 · AI · contact PI
Structural studies of Ebola VP35 mediated immune evasion mechanisms$137,516
R01 · FY2011 · AI · contact PI
Structural studies of Ebola VP35 mediated immune evasion mechanisms$523,715
R01 · FY2010 · AI · contact PI
Structural studies of Ebola VP35 mediated immune evasion mechanisms$341,945
R01 · FY2009 · AI · contact PI